Literature DB >> 1610490

A study of interferon-gamma and interleukin-2 production in premature neonates and neonates with intrauterine growth retardation.

S Saito1, Y Kato, M Maruyama, M Ichijo.   

Abstract

Mononuclear cells from aborted fetuses, preterm infants, intrauterine growth retardation (IUGR) fetuses, and mature infants were stimulated with OK432 and PHA to study their effect on the production of interferon gamma (IFN-gamma) and interleukin-2 (IL-2), respectively. IFN-gamma production was reduced in the mature delivery group, while its production in preterm delivery and IUGR groups was markedly reduced compared to those in adults and the mature delivery group. Reduced IFN-gamma production in preterm delivery and IUGR groups was attributable neither to a decrease in T-cells nor to enhanced sensitivity of T-cells to prostaglandins. Unlike IFN-gamma production, IL-2 production in preterm delivery groups was higher than that in adults; its production in the IUGR group was comparable to that in adults. In addition, both IFN-gamma and IL-2 production in premature delivery cases was enhanced when these cases were exposed to the stress of infection.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1610490     DOI: 10.1111/j.1600-0897.1992.tb00725.x

Source DB:  PubMed          Journal:  Am J Reprod Immunol        ISSN: 1046-7408            Impact factor:   3.886


  3 in total

1.  Function and phenotype of immature CD4+ lymphocytes in healthy infants and early lymphocyte activation in uninfected infants of human immunodeficiency virus-infected mothers.

Authors:  K C Rich; J N Siegel; C Jennings; R J Rydman; A L Landay
Journal:  Clin Diagn Lab Immunol       Date:  1997-05

Review 2.  Polyunsaturated fatty acids and T-cell function: implications for the neonate.

Authors:  C J Field; M T Clandinin; J E Van Aerde
Journal:  Lipids       Date:  2001-09       Impact factor: 1.880

Review 3.  Soluble mediators regulating immunity in early life.

Authors:  Matthew Aaron Pettengill; Simon Daniël van Haren; Ofer Levy
Journal:  Front Immunol       Date:  2014-09-24       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.